Uncategorized
ANCHOR, MARINA and HORIZON trials show mixed visual outcomes at 7 years
One-third of patients who participated in the ANCHOR and MARINA trials had good visual outcomes and one-third had poor visual outcomes at about 7 years, according to a study.The Seven-Year Observational Update of Macular Degeneration Patients Post-MARINA/ANCHOR and HORIZON Trials (SEVEN-UP study) included 65 patients with exudative age-related macular degeneration who underwent intensive Lucentis (ranibizumab, Genentech) therapy in one of the trials.Investigators assessed Snellen best corrected visual acuity, change in letter scores and anatomic outcomes.